<DOC>
	<DOCNO>NCT02685774</DOCNO>
	<brief_summary>This study randomize , open-label , single dose , 2-way crossover study compare pharmacokinetic characteristic CKD-395 0.25/500 mg healthy male volunteer .</brief_summary>
	<brief_title>A Clinical Study Compare Pharmacokinetic Characteristics CKD-395 0.25/500mg Healthy Male Volunteers</brief_title>
	<detailed_description>To healthy male subject twenty six ( 26 ) , follow treatment administer dose period feed condition ( high fat meal ) wash-out period minimum 7 day . Treatment A ( Reference Drug ) : DuvieTM Tab . 0.5mg 1T + Glucophage XR Tab . 500mg 2T Treatment B ( Test Drug ) : CKD-395 0.25/750mg Tab . 2T Pharmacokinetic blood sample collect 48hrs . Safety pharmacokinetic assess .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . A healthy male whose age 19 year old visit initial screen test 2 . Body mass index ( BMI ) 17.5 ~ 30.5 kg/m^2 body weight must 55kg Body mass index ( BMI ) = weight ( kg ) / height ( ) ^2 3 . A male congenital chronic disease three year , history symptom internal treatment , knowledge area 4 . Due special characteristic drug , participators must qualify clinical screening examine hematology test blood chemistry analysis , urinary test , electrocardiogram ( ECG ) , etc . 5 . The participant must volunteer sign inform consent document proven Chonbuk National University IRB join study show give informed purpose test special characteristic drug . 6 . The participant must ability willingness participate throughout entire trial 1 . A person history symptom clinically aware blood , kidney , internal secretion , gastrointestinal , urinary system , cardiovascular , liver , mental , nervous , allergic ( except subclinical seasonal allergy treat injection ) disease . 2. Who history gastrointestinal related disease affect drug absorption ( esophageal achalasia , esophagostenosis , esophageal disease , Crohn 's disease ) surgery ( except simple appendectomy herniotomy ) 3. Who follow result examination a. ALT AST &gt; twice high normal value 4. Who constantly intake 210 g/week alcohol within 6 month screen . ( cup beer ( 5 % ) ( 250mL ) = 10 g , shot soju ( 20 % ) ( 50mL ) = 8 g , glass wine ( 12 % ) ( 125 mL ) = 12 g ) 5. Who participate clinical test take test bioequivalence drug 3 month first clinical drug trial 6 . Whose blood pressure &gt; 140 mmHg ( systolic blood pressure ) &gt; 90 mmHg ( diastolic pressure ) 7. Who medical history alcohol drug abuse . 8. Who take drug control metabolic rate ( activation inhibition ) 30 day first take clinical test drug 9. Who smoke 20 cigarette per day 10. Who take prescribe drug overthecounter drug 10 day take first clinical test drug 11. Who participate whole blood donation 2 month first take clinical test drug platelet donation 1 month first take clinical test drug . 12. Who potent increase danger participate clinical trial interrupt interpret test result serious chronic medical mental status issue result screen examination . 13. Who history extreme sensitivity drug contain Rosiglitazone drug similar effect Rosiglitazone ( Pioglitazone ) , drug contain ingredient Metformin biguanidine drug 14. Who serious heart failure congestive heart failure must drugtreated 15 . A patient hepatopathy 16 . A patient severe nephropathy 17. Who diabetic ketoacidosis diabetic coma , type 1 diabetes , history acute metabolic acidosis ketoacidosis 18 . A patient serious infectious disease severe injury surgery 19. Who Galactose intolerance , LAPP lactose intolerance , glucosegalactose malabsorption genetic disorder 20 . A patient kidney disease renal insufficient cause cardiovascular collapse ( shock ) acute myocardial infarction ( male high serum creatinine 1.5mg / dL , less creatinine clearance 80 mL / min ) 21 . A patient test inject radiological iodine contrast agent blood vessel ( ex : intravenous urography , intravenous cholangiography , angiography , use contrast medium computer tomography , etc . ) 22. Who severe systematic infection severe trauma 23. Who nutritional status , starvation , debilitate condition , pituitary dysfunction , adrenal insufficiency patient 24. Who respiratory dysfunction , gastrointestinal disease 25. Who unable take high fat food 26. Who limit intake grapefruit grapefruit contain food 7 day first dose clinical test drug collect pharmacokinetic blood sample 27 . Test subject willing unable comply guideline describe protocol 28 . A person determine unsuitable participate test researcher</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>